β-Cell Loss and β-Cell Apoptosis in Human Type 2 Diabetes Are Related to Islet Amyloid Deposition  by Jurgens, Catherine A. et al.
The American Journal of Pathology, Vol. 178, No. 6, June 2011
Copyright © 2011 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.ajpath.2011.02.036Cell Injury, Repair, Aging, and Apoptosis
-Cell Loss and -Cell Apoptosis in Human Type 2
Diabetes Are Related to Islet Amyloid DepositionCatherine A. Jurgens,* Mirna N. Toukatly,*
Corinne L. Fligner,† Jayalakshmi Udayasankar,*
Shoba L. Subramanian,* Sakeneh Zraika,*
Kathryn Aston-Mourney,* Darcy B. Carr,‡
Per Westermark,§ Gunilla T. Westermark,¶
Steven E. Kahn,* and Rebecca L. Hull*
From the Division of Metabolism, Endocrinology and Nutrition,*
Veterans Affairs Puget Sound Health Care System and University
of Washington, Seattle, Washington; the Departments of
Pathology,† and Obstetrics & Gynecology,‡ University of
Washington, Seattle, Washington; and the the Departments of
Immunology, Genetics and Pathology,§ and Medical Cell
Biology,¶ Uppsala University, Uppsala, Sweden
Amyloid deposition and reduced -cell mass are path-
ological hallmarks of the pancreatic islet in type 2
diabetes; however, whether the extent of amyloid de-
position is associated with decreased -cell mass is
debated. We investigated the possible relationship
and, for the first time, determined whether increased
islet amyloid and/or decreased -cell area quantified
on histological sections is correlated with increased
-cell apoptosis. Formalin-fixed, paraffin-embedded
human pancreas sections from subjects with (n  29)
and without (n  39) diabetes were obtained at au-
topsy (64  2 and 70  4 islets/subject, respectively).
Amyloid and  cells were visualized by thioflavin S
and insulin immunolabeling. Apoptotic  cells were
detected by colabeling for insulin and by TUNEL. Di-
abetes was associated with increased amyloid deposi-
tion, decreased -cell area, and increased -cell apop-
tosis, as expected. There was a strong inverse
correlation between -cell area and amyloid deposi-
tion (r0.42, P< 0.001). -Cell area was selectively
reduced in individual amyloid-containing islets from
diabetic subjects, compared with control subjects,
but amyloid-free islets had -cell area equivalent to
islets from control subjects. Increased amyloid de-
position was associated with -cell apoptosis (r 
0.56, P < 0.01). Thus, islet amyloid is associated with
decreased -cell area and increased -cell apoptosis,
suggesting that islet amyloid deposition contributes
to the decreased -cell mass that characterizes type 2
2632diabetes. (Am J Pathol 2011, 178:2632–2640; DOI:
10.1016/j.ajpath.2011.02.036)
Type 2 diabetes is characterized by insulin resistance
and -cell failure,1 the latter resulting from reductions in
-cell function2,3 and/or -cell mass.4–6 Together, these
contribute to impaired insulin release and the inability to
maintain euglycemia without glucose-lowering therapy.
A pathological hallmark of the pancreatic islet in type 2
diabetes is islet amyloid deposition. These deposits oc-
cur in the majority of patients with diabetes,5,7–10 but
have also been reported in a small proportion of subjects
who are apparently nondiabetic (but may have undiag-
nosed abnormalities in glucose metabolism), and espe-
cially in those who are older.7,11 The formation of islet
amyloid occurs by aggregation of islet amyloid polypep-
tide (IAPP, or amylin),12,13 which is normally cosecreted
with insulin by the  cell.14
In vitro studies have demonstrated that the process
of IAPP aggregation is cytotoxic, resulting in -cell
apoptosis.15,16 In vivo studies of spontaneous islet am-
yloid deposition in nonhuman primates and in domestic
cats,17–20 as well as in transgenic rodent models of
islet amyloid formation,21–23 have shown that the accu-
mulation of islet amyloid formation precedes fasting
hyperglycemia and is associated with decreased
-cell function and -cell loss.
Human studies investigating the relationship between
-cell mass and islet amyloid are more limited. Several
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position in histological sections from the same human
pancreas samples.5,8,9,24,25 Only two studies have made
assessments of correlations between these measures,
however, and the findings are contradictory.8,24 One
study identified a significant correlation between in-
creased amyloid deposition and -cell loss,24 but the
other found that no such relationship exists.8 In addi-
tion, none of these studies examined whether the loss
of  cells occurs selectively in amyloid-laden islets and
whether islet amyloid deposition, or changes in -cell
area, are associated with increased -cell apoptosis
and/or decreased -cell replication. With the present
study, we sought to provide further insight into the
relationship between islet amyloid deposition and de-
creased -cell area in humans and to explore, for the
first time, whether islet amyloid deposition is associ-
ated with increased -cell apoptosis and/or reduced
-cell replication.
Materials and Methods
Subjects
We studied 29 patients with diabetes, identified by type 2
diabetes diagnosis in their medical records, with or with-
out the use of antidiabetic medications. We also studied
39 nondiabetic control subjects who did not meet these
criteria and who additionally had a random glucose of7
mmol/L. Individuals with a history of pancreatic cancer,
pancreatitis, end-stage liver disease, hepatitis, organ
transplantation, or chronic glucocorticoid treatment were
excluded. The study was approved by institutional review
boards at the University of Washington and the VA Puget
Sound Health Care System.
Pancreatic tissue was obtained during autopsies per-
formed at the University of Washington and the VA Puget
Sound Health Care System. Specimens were routinely
sampled from the body of the pancreas; however, au-
topsy records did not always indicate from what specific
region of the organ the pancreas samples had been
obtained. Specimens were included in the study only if
they showed no or minimal autolysis (as assessed by
C.L.F.and R.L.H.). Pancreatic weight was not available;
data are therefore presented as -cell area, rather than
-cell mass.
Histological Assessments
Formalin-fixed, paraffin-embedded pancreas specimens
were cut into sections 10-m thick, and three consecu-
tive sections were labeled. All sections were labeled with
insulin antibody [I2018, clone K36AC10 at 1:2000 (Sig-
ma-Aldrich, St. Louis, MO) or A0564 at 1:50 (Dako,
Carpinteria, CA)] to visualize  cells and were colabeled
with either thioflavin S to detect amyloid deposits, with
deoxynucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL) (In Situ Cell Death Detection Kit; Roche
Applied Sciences, Indianapolis, IN) to detect apoptotic
cells, or with Ki-67 (MIB-1 at 1:50; Dako) to detect repli-
cating cells. Secondary antibodies for insulin immuno-labeling were Cy3-conjugated goat-anti-mouse (Jack-
son ImmunoResearch, West Grove, PA) or Alexa Fluor
488-conjugated goat-anti guinea pig immunoglobulins
(Invitrogen, Carlsbad, CA). For detection of Ki-67 la-
beling, biotinylated goat anti-mouse immunoglobulins
followed by streptavidin-Cy3 were used (both from
Jackson ImmunoResearch). All sections were counter-
stained with Hoechst 33258 (2 g/mL; Sigma-Aldrich)
to identify nuclei.
Microscopy
Histological assessments were made on all islets within a
region of pancreas representative of the whole section.
The data collector was blinded to the diabetes status of
each specimen. The average number of islets scored per
subject was 64 2 in diabetic subjects and 70 4 in the
control group (P  0.20). Neither the area of the sections
assessed (17.8  1.7 versus 20.6  1.7 mm2, diabetes
versus control; P  0.27) nor islet density (4.4  0.4
versus 4.2 0.4 islets/mm2, diabetes versus control; P
0.7) differed between groups. Islet area was defined by
manually circumscribing each islet edge, identified visu-
ally by morphological characteristics of the tissue viewed
on the thioflavin S channel and calculating the area of that
region of interest. The lower cutoff for islet size was 1000
m2 (15 cells). Insulin-positive area (-cell area) and
thioflavin S-positive area (amyloid area) were determined
using a computer-based quantitative system as de-
scribed previously.21,26
Amyloid prevalence was calculated as the number
of islets containing amyloid divided by the total number
Table 1. Subject Characteristics, Causes of Death, and Diabetes
Medications
Variable
Type 2
Diabetes Controls P value
Clinicodemographic
characteristics
Sample size n  29 n  39
Age (years) 63.9 13.1 61.7  19.3 0.58
Sex (% female) 34.5 46.2 0.34
BMI (kg/m2) 30.6  6.8 26.6  7.7 0.03
Plasma glucose
(mmol/L)
8.9  2.4 5.5  0.6 0.001
Diabetes duration
(years)*
10  2 n/a
Cause of death, n (%)
CVD/stroke 10 (26) 9 (23)
Cancer 6 (21) 13 (33)
Pulmonary 3 (10) 8 (21)
Surgical 2 (7) 2 (5)
Infection 3 (10) 6 (15)
Gastrointestinal 5 (17) 1 (3)
Diabetes medication,
n (%)
None 4 (14)
Oral 11 (38)
Insulin 11 (38)
Unknown 3 (10)
Data are reported as means  SD.
BMI, body mass index; CVD, cardiovascular disease; n/a, not appli-cable.
*Diabetes duration data were available only for 13/29 subjects.
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Age (years)/
Sex
BMI
(kg/m2)
Blood glucose
(mmol/L)
Diabetes duration
(years) Diabetes medication Cause of death
Diabetes group
62/F 30.9 8.53 ND glyburide, insulin pulmonary embolism
78/F 28.3 7.67 2 diet GI hemorrhage
59/M 32.6 7.90 8 insulin cardiac arrest
59/M 38.4 7.39 ND insulin leukemia
69/F 21.2 9.50 ND metformin malignancy
81/M 31.4 5.63 ND glyburide, metformin aortic dissection
68/M 27.2 11.42 ND metformin GI hemorrhage
52/M 26.3 9.07 ND none cardiopulmonary failure
61/M 29.7 6.85 14 insulin respiratory failure
71/F 21.3 9.39 10 glyburide coronary artery disease
51/F 41.2 11.11 ND glyburide, insulin malignancy
62/M 35.9 7.46 ND insulin in TPN abdominal hemorrhage
80/F 29.1 8.89 20 acetohexamide,insulin coronary artery disease
61/M 36.3 8.92 12 diet, glipizide sepsis
58/M 34.4 8.29 ND insulin coronary artery disease
71/M 37.5 6.50 27 insulin postoperative complications
74/F 36.0 13.17 ND unknown aspiration pneumonia
37/M 39.7 7.69 3 unknown cardiomyopathy
71/F 21.6 ND 12 glyburide coronary artery disease
70/F 32.8 10.33 ND oral hypoglycemic, unspecified abdominal hemorrhage
69/M 21.3 7.06 10 glyburide coronary artery disease
64/M 22.5 6.47 ND insulin sepsis
40/M 41.2 10.17 ND diet, metformin postoperative complications
28/M 35.8 7.67 1 metformin myelodysplastic syndrome
82/M 25.6 17.06 ND glipizide sepsis
63/F 38.8 10.50 12 insulin malignancy
63/M 26.5 7.11 ND diet malignancy
68/M 25.0 ND ND diet cardiac arrest
82/M 19.0 7.50 2 diet sepsis
Control group
87/F 33.0 5.14 NA NA valvular heart disease
62/M 23.4 5.58 NA NA malignancy
34/M 17.5 5.14 NA NA malignancy
63/F 18.7 5.23 NA NA malignancy
54/F 49.3 5.94 NA NA postoperative complications
82/F 40.9 4.72 NA NA perforated duodenal ulcer
61/F 24.3 5.58 NA NA abdominal hemorrhage
65/M 20.5 6.31 NA NA stroke
21/F 32.2 4.63 NA NA pulmonary embolism
64/M 18.7 6.47 NA NA malignancy
65/F 40.1 4.79 NA NA pulmonary veno-occlusive disease
67/M 24.1 5.12 NA NA malignancy
52/M 24.1 5.26 NA NA malignancy
77/F 26.3 6.08 NA NA sepsis
34/M 28.8 5.44 NA NA malignancy
68/F 18.6 4.86 NA NA malignancy
89/M 17.8 6.07 NA NA malignancy
57/F 19.2 5.87 NA NA malignancy
75/M 22.6 4.94 NA NA pneumonia
66/F 25.7 5.43 NA NA respiratory failure
50/M 28.0 5.50 NA NA cardiac failure
45/M 29.8 4.53 NA NA cardiac arrest
83/F 19.8 5.15 NA NA cardiac arrest
44/F 18.0 5.18 NA NA meningitis
20/F 22.8 4.60 NA NA pulmonary hypertension
42/F 34.0 5.39 NA NA sepsis
88/F 29.2 6.16 NA NA respiratory failure
81/M 27.1 5.56 NA NA respiratory failure
58/M 24.9 5.44 NA NA stroke
19/M 32.7 6.22 NA NA malignancy
46/F 28.1 6.47 NA NA sepsis
78/F 42.4 3.78 NA NA abdominal hemorrhage
75/M 20.9 5.83 NA NA malignancy
72/M 34.9 5.56 NA NA multiple myeloma
82/M 32.5 6.06 NA NA sepsis
94/M 21.9 5.22 NA NA sepsis(table continues)
ata; TPN
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divided by the total islet area (m2), and -cell area as
insulin-positive area (m2) or as total insulin-positive
area (m2) divided by the total islet area (m2). All
measures, except absolute -cell area, were ex-
pressed as percentages.
Assessment of -cell apoptosis and replication was
performed in a randomly selected subset of samples.
Power calculations showed that, for a twofold difference
in apoptosis with variability similar to that in published
studies,5 a sample size of approximately 15 subjects
would be sufficient. -Cell apoptosis was analyzed on
sections from 16 control subjects and 13 diabetic sub-
jects (comprising an average of 6322  530 and 5667 
412 islet cells, respectively); for -cell replication, sec-
tions from 15 control subjects and 17 diabetic subjects
were examined (comprising an average of 5324  561
and 5356  587 islet cells, respectively). The demo-
graphic characteristics of these subjects and histological
measures of islet area, islet amyloid deposition, and
-cell area in each subgroup did not differ from their
respective whole cohorts. -Cell apoptosis and replica-
tion were calculated as the average number of TUNEL-
positive or Ki-67-positive  cells per islet, normalized to
-cell/islet area, according to approaches described pre-
viously.5 The range for TUNEL-positive  cells was 0% to
5.2%; the range for Ki-67-positive  cells was 0% to
0.75%. Note that for -cell replication data, Ki-67 and
insulin costained cells were absent in 20% of cases. In all
these cases, however, Ki-67 positive cells were visible
either in non-insulin-positive islet cells or in exocrine pan-
creas, indicating that this was a genuine lack of prolifer-
ating  cells and not a limitation of the Ki-67 labeling
technique.
To determine islet size distribution, measures from is-
lets of all diabetic subjects (n  1844 islets) were com-
pared with those of the control subjects (n  2726 islets),
using both raw and log-transformed data. To examine
whether there was a difference in islet area and -cell
area between amyloid-positive and amyloid-negative is-
lets, data from each individual islet from all diabetic sub-
jects were categorized as amyloid positive (n  859
islets) or negative (n  985 islets). Islet area and -cell
area were then determined and compared with all islets
in control subjects (n  2726 islets) and with only those
islets from control subjects that were amyloid negative
(n  2574 islets).
Statistical Analysis
Data for variables that were normally distributed are re-
Table 2. Continued
Age (years)/
Sex
BMI
(kg/m2)
Blood glucose
(mmol/L)
Diabetes duration
(years)
68/M 24.0 5.17 NA
60/M 15.9 6.94 NA
57/M 22.8 5.56 NA
F, female; GI, gastrointestinal; M, male; NA, not applicable; ND, no dported as means  SD for subject characteristics andmeans  SEM for all other data. Non-normally distributed
data are presented as median and interquartile range
(IQR). For data analysis purposes, non-normally distrib-
uted data were transformed (ln, square, or square root).
Groups of data with normal distribution before or after
transformation were compared using a Student’s t-test.
For data that were not normally distributed after transfor-
mation, a Mann-Whitney U-test was used. Regression
analyses were performed using Spearman’s correlation
with or without adjustments for diabetes treatment and
cause of death. A 2 test was used to determine the
difference in distributions for categorical variables be-
tween the diabetes and control groups. A P value of
0.05 was considered significant.
Results
Subject Characteristics
Group characteristics are presented in Table 1 and char-
acteristics for individual subjects are presented in Table
2. Subjects were well matched for age and sex, although
those with diabetes were heavier. As expected, glucose
levels of diabetic subjects were significantly higher than
control subjects. The mean time since diagnosis of dia-
betes was 10 years. The number of diabetic subjects
treated with diet, oral medications, or insulin are reported
in Tables 1 and 2; where subjects were treated with a
combination of insulin and other antidiabetic medica-
tions, they were classified for the group data as insulin
treated. The causes of death did not differ significantly
between the two groups.
To control for the difference in body mass index (BMI)
between groups, a subset of subjects (n  19 per group)
were matched case by case for sex (47% females in each
group), age (67  12 versus 68  9 years for diabetic
versus control subjects), and BMI (29.5 6.1 versus 29.1
8.6 kg/m2). Blood glucose levels were significantly ele-
vated in diabetic subjects in this smaller cohort (9.1 2.7
versus 5.3  0.62 mmol/L, P  0.001). The remaining
characteristics in these two subgroups did not differ be-
tween the groups and were not different from those of the
remainder of their respective cohorts.
Islet Amyloid Deposition
Almost all individuals with diabetes (97%) demon-
strated some islet amyloid deposition (Figure 1A); am-
yloid was also present in 25% of the nondiabetic con-
trol subjects, (Figure 1B). Both amyloid prevalence and
iabetes medication Cause of death
NA respiratory failure
NA respiratory failure
NA cardiac arrest
, total parenteral nutrition.Dseverity were much higher in diabetic subjects (Figure
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islet amyloid prevalence and severity were still signifi-
cantly higher in diabetic subjects (54  8% versus 9 
5% and 12.5  2.4% versus 1.2  0.8%, respectively;
P  0.001 for both).
In the whole cohort, islet amyloid prevalence and
severity were strongly correlated, both in all subjects
(Figure 1E) and in diabetic subjects (r  0.83, P 
0.001). Islet amyloid prevalence was positively corre-
lated with age in all subjects (r  0.31, P  0.01) and
in diabetic subjects (r  0.43, P  0.02). However,
neither amyloid prevalence nor amyloid severity was
associated with sex, BMI, blood glucose, diabetes du-
ration, or diabetes medication. Given that islet amyloid
was detected in a proportion of control subjects, we
examined whether any characteristics were associated
with the presence of amyloid deposition in this group.
Those control subjects with islet amyloid did not differ
from those without islet amyloid in terms of age, sex,
Figure 1. Islet amyloid deposition in individuals with diabetes (n  29) and
control subjects (n  39). A: Representative images of islets stained for
insulin (red) and thioflavin S (green). The left andmiddle images show islets
from individuals with diabetes, with amyloid severities of 6% and 32%,
respectively. The image at the right shows an islet from a control subject,
amyloid negative. Scale bar  50 m. B–E: Quantitative analysis. The pro-
portion of subjects with any detectable islet amyloid (B), the mean islet
amyloid prevalence expressed as % amyloid-positive islets (C), and mean
islet amyloid severity expressed as amyloid positive area/islet area  100%
(D) were all significantly greater in diabetic subjects than control subjects.
Individual points represent data for each subject, with mean  SEM for the
two groups also depicted (C and D). Islet amyloid prevalence and severity
were correlated in a linear manner (E); solid circles indicate individuals
with diabetes, and open triangles indicate control subjects (r  0.87). *P 
0.001 versus control subjects.BMI, or blood glucose.Islet Area and -Cell Area
The distribution of islet areas within each group was not
normal; however, the distribution was very similar be-
tween groups (Figure 2, A and B). As a result, median
islet area did not differ (P  0.87, Figure 2C). Similarly,
islet area did not differ in the subset of subjects matched
for BMI [9345 (IQR 1678) versus 8399 (IQR 1843) m2,
P  0.2], and islet area did not correlate with BMI in the
whole cohort (r  0.69, P  0.58). Individuals with type 2
diabetes had a significantly lower absolute -cell area,
compared with control subjects (P  0.05, Figure 2D).
-Cell area remained significantly lower in the diabetic
group when normalized to islet area (P  0.05, Figure
2E). In the subgroup of subjects matched for BMI, abso-
lute -cell area and -cell/islet area were both signifi-
cantly lower in individuals with diabetes [2770 (IQR 319)
versus 3900 (IQR 926) m2 and 34.7 3.2 versus 47.5
2.1%, respectively; P  0.05 for both).
Figure 2. Measurements of cross-sectional islet and -cell areas in individ-
uals with diabetes (n  29) and control subjects (n  39). Islet size distri-
bution was determined in individuals with diabetes (A) and in control sub-
jects (B). Median islet area (C) was identical between groups. Median -cell
area (D) and mean -cell area normalized to islet area, expressed as insulin
positive area/islet area  100% (E), were significantly lower in individuals
with diabetes; individual points represent data for each subject, with mean
SEM for the two groups also depicted. For box plots, boxes denote the 25th
to 75th percentiles and whiskers denote 5th and 95th percentiles; data that
fall outside the range of the 5th to 95th percentiles are outliers and are shown
as circles (C and D). *P  0.05 versus control subjects.
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and -Cell Area
In the whole cohort, there was an inverse relationship
between islet amyloid severity and both absolute -cell
area (Figure 3A) (r  0.42, P  0.001) and -cell area/
islet area (Figure 3B) (r0.76, P 0.05). In individuals
with diabetes, these correlations were stronger than for
the whole cohort for both measures of -cell area (r 
0.60, P 0.001 for absolute -cell area; r0.81, P
0.001 for -cell area/islet area). After adjustment for dia-
betes treatment and cause of death, the relationships
between islet amyloid severity and both absolute -cell
area and -cell area/islet area remained significant (P 
0.005 for both). In the control group, there was no signif-
icant association between islet amyloid severity and
Figure 3. Increased islet amyloid deposition was associated with reduced
-cell area. Correlation is shown among all subjects between amyloid sever-
ity and absolute -cell area (r0.42 and P 0.001) (A), or -cell area/islet
area (r  0.76 and P  0.001) (B), in individuals with diabetes (solid
circles) and in control subjects (open triangles).-cell area (r  0.07, P  0.66 for absolute -cell areaand r  0.12, P  0.47 for -cell area/islet area). Islet
amyloid prevalence was also significantly negatively cor-
related with absolute -cell area (r  0.33, P  0.01 for
the whole cohort; r  0.35, P  0.07 for diabetic sub-
jects) and was more strongly correlated with decreased
-cell area/islet area (r  0.75, P  0.001 for the whole
cohort; r0.81, P 0.001 for diabetic subjects). In the
control group alone, there was no significant association
between islet amyloid prevalence and -cell area (r 
0.09, P  0.61 for absolute -cell area and r  0.12,
P  0.45 for -cell area/islet area).
To further examine the relationship between amyloid
deposition and reduced -cell area, we determined
whether loss of -cell area occurred selectively in amy-
loid-laden islets. Data from all islets from diabetic individ-
uals, grouped as amyloid positive (n  859 islets) or
amyloid negative (n 985 islets), were compared with all
control islets (n  2726, Figure 4). Amyloid-laden islets
from diabetic subjects were bigger than islets without
amyloid (P  0.001, Figure 4A), and -cell/islet area was
significantly reduced in amyloid-laden islets (P  0.001,
Figure 4B). There was no difference in -cell/islet area
between amyloid-negative islets from diabetic subjects
and all islets from control subjects (P  0.99). When data
from the islets obtained from the individuals with diabetes
were compared with only amyloid-negative control islets
(n  2574), the findings were the same (data not shown).
-Cell Apoptosis and Replication
Finally, we sought to determine whether the increased
islet amyloid severity and decreased -cell area ob-
served in individuals with diabetes was associated with
changes in -cell apoptosis or replication (Figure 5, A
and B). The frequency of -cell apoptosis in diabetic
subjects was 4.5-fold higher than that for control subjects
(P  0.01, Figure 5C), whereas the average frequency of
-cell replication was similar between groups (P  0.63,
Figure 5D). For the subset of individuals matched for BMI,
-cell apoptosis was significantly higher in diabetic sub-
jects (0.091  0.022 versus 0.013  0.010%, n  8 and
6, respectively; P  0.01), with no difference in -cell
replication (0.008  0.004 versus 0.003  0.001%, n 
10 and 5, respectively; P  0.3).
In the whole cohort, increased amyloid severity was
significantly associated with -cell apoptosis (r  0.56,
P  0.01; Figure 5E) and tended to be associated with
increased -cell apoptosis in diabetic subjects (r  0.42,
P  0.16). Furthermore, -cell apoptosis was negatively
associated with -cell area, both in all subjects (r 
0.33, P  0.07; Figure 5F) and in those with diabetes
(r  0.59, P  0.05). For these correlation analyses,
absolute -cell area was used, because the -cell apop-
tosis measure incorporates the normalized -cell area/
islet area measure.
Discussion
We have shown that in type 2 diabetes the quantity of
amyloid deposited in islets is strongly associated with
2638 Jurgens et al
AJP June 2011, Vol. 178, No. 6decreased -cell area. Previously published human stud-
ies investigating this relationship provided contradictory
information.8,24 We think that our data help to resolve this
discrepancy. Moreover, we made the novel observation
that -cell area is reduced only in amyloid-positive islets
from diabetic subjects, highlighting the potential impor-
tance of amyloid in the loss of  cells in this disease. In
addition, our study is the first to examine the relationship
between amyloid deposition and -cell apoptosis. We
found, in accord with previous findings,5 that -cell apop-
tosis was significantly increased in subjects with type 2
diabetes. In addition, and for the first time, we report that
-cell apoptosis is significantly associated with both in-
Figure 4. Median islet (A) and -cell area/islet area (B) in amyloid-positive
islets from individuals with diabetes (n  859 islets), amyloid-negative islets
from individuals with diabetes (n  985 islets), and islets from control
subjects (n  2726 islets). Amyloid-laden islets were significantly larger (A),
but had significantly lower -cell area/islet area (B). Islet area and -cell
area/islet area were equivalent between amyloid-negative islets from indi-
viduals with diabetes and control subjects. For box plots, boxes denote the
25th to 75th percentiles and whiskers denote 5th and 95th percentiles. *P 
0.001 versus control subjects.creased islet amyloid severity and decreased -cell area.Islet amyloid was present to some degree in 97% of
individuals with diabetes, in accord with previous re-
ports.5,7,8 Increased islet amyloid prevalence was asso-
ciated with age in both the whole cohort and the diabetes
group alone, consistent with the progressive accumula-
tion of amyloid deposits. Neither islet amyloid deposition
nor -cell/islet area was related to diabetes duration;
however, data on diabetes duration were available in only
13 subjects, and even under optimal circumstances the
measure is subjective, given that diabetes often goes
undiagnosed for long periods of time. Thus, it is not
surprising that we did not find a relationship between
these two measures. Some studies have found a com-
plete lack of islet amyloid in their control subjects.8,25 In
the present study, however, we detected amyloid in at
least one islet in 25% of nondiabetic subjects, in accord
with other reports.7,11 Although islet amyloid deposition
has previously been described in older subjects without
known diabetes,7,11 we failed to observe a relationship
between amyloid and age in our control subjects. This
lack of correlation may be due to the small number of
Figure 5. Representative examples of staining for -cell apoptosis (A) with
TUNEL (green), insulin (red), and Hoechst 33258 (blue) and for -cell
replication (B) with Ki-67 (red), insulin (green), and Hoechst 33258 (blue).
Arrows indicate TUNEL- or KI-67-positive  cells; arrowheads indicate
TUNEL-positive non- cells. Mean -cell apoptosis (C) was significantly
higher in islets from individuals with diabetes (n  13), compared with
control subjects (n  16). Mean -cell replication (D) did not differ between
islets from individuals with diabetes (n  15) and control subjects (n  17);
P  0.63. -cell apoptosis was significantly associated with increased islet
amyloid severity (E), r 0.56 and P 0.01, and tended to be associated with
decreased absolute -cell area (F), r  0.33 and P  0.07. Solid circles:
diabetes; open triangles, controls. *P  0.05 versus control subjects; scale
bar  50 m.
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decrease in -cell area in individuals with diabetes, com-
pared with control subjects, which is within the range
reported previously.4–6,8,9 The large variation of -cell
loss reported in diabetes between and even within stud-
ies may be due to the large variability in -cell area in
both healthy control subjects and subjects with type 2
diabetes,6,9 which we observed also in our cohort.
We found a highly significant inverse relationship be-
tween the magnitude of islet amyloid deposition and each
measure of -cell area in diabetes, with 60% to 80% of
the variance in -cell area being explained by amyloid
deposition. Furthermore, we made the novel observation
that -cell area in amyloid-negative islets from diabetes
and control subjects was identical, but -cell area was
significantly reduced in amyloid-positive islets from dia-
betes subjects. Collectively, our findings strongly support
a role for islet amyloid formation in the loss of  cells that
is involved in the pathogenesis of type 2 diabetes.
IAPP aggregation/amyloid formation has been shown
to result in -cell apoptosis in cultured cells and islets, as
well as in pancreas from animal models.15,16,23,27–30 In-
hibition of islet amyloid formation results in decreased
-cell apoptosis in cultured transgenic mouse islets29
and human islets,28,30 further supporting a causal role
between amyloid formation and -cell apoptosis. In keep-
ing with a previous study,5 we found -cell apoptosis to
be markedly increased in type 2 diabetes. Furthermore,
we found that increased islet amyloid severity in all sub-
jects was associated with increased -cell apoptosis,
suggesting that the process of amyloid deposition may
also be an important cause of -cell loss in humans.
However, this correlation was not significant when the
diabetes cohort was analyzed separately; this may be
due to the smaller number of subjects for which -cell
apoptosis was determined.
In addition to the mature amyloid deposits detected in
the present study by thioflavin S staining, other IAPP-
derived aggregates may also contribute to -cell toxicity
in diabetes. Recent studies suggest that early aggre-
gates of IAPP formed during the process of amyloid de-
position (rather than the amyloid deposits themselves)
are cytotoxic and thereby induce -cell death.16 Small
aggregates or oligomers of IAPP have been reported to
be present in  cells from subjects with type 2 diabe-
tes31,32 and are therefore postulated to represent the
toxic form of IAPP. Of note, in the present study we
showed that amyloid-negative islets from diabetic sub-
jects did not have reduced -cell area relative to those
from nondiabetic control subjects. Thus, if small aggre-
gates of IAPP were present in amyloid-negative islets
from diabetic subjects, they do not seem to have resulted
in measurable -cell loss. However, and importantly, as
we have discussed in a recent review,33 the reagents
available to detect these small aggregates require further
validation for use in human pancreas sections, and there-
fore any conclusions drawn regarding their location and
role have to be somewhat circumspect.
A limitation of the present study is that diabetes status
was determined from a retrospective medical record re-
view. It is possible that we misclassified subjects, or thatsubjects treated with insulin may have had type 1 diabe-
tes. If so, however, this should have made it more difficult
to demonstrate the relationship between islet amyloid
deposition and -cell area that we observed in our study
cohort. Another limitation of our work is that the region of
the pancreas sampled was not recorded in all cases. Not
having sections representing different portions of the
pancreas may have resulted in an under- or overestima-
tion of the amount of islet amyloid deposition. However,
again we were still able to detect significant relationships
between the variables of interest despite this potential
source of variability. Furthermore, studies performed on
both human IAPP transgenic mice and human pancreas
have shown that amyloid develops throughout the pan-
creas,8,21 suggesting that not knowing the origin for all
pancreas samples is unlikely to have substantially influ-
enced our data.
Finally, the present study is cross-sectional and can
provide only correlative data with respect to islet amyloid
deposition and its role in -cell loss in type 2 diabetes.
Two important points are worth raising in this regard. The
first is that, although our data support the concept that
amyloid deposition contributes to -cell toxicity in type 2
diabetes, in accord with data from in vitro studies and
from in vivo animal data,15,16,23,27–30 the reverse may also
be true; that is, amyloid deposition may occur as a result
of the increased -cell death that occurs in diabetes, or
amyloid deposition may accompany but not contribute
to -cell loss. The second important point is that it is
not possible from a study of this kind to determine
whether islet amyloid deposition and/or the associated
reduction in the -cell mass are related (and if related,
to what extent) to impaired insulin secretion and/or
glycemic control.
In summary, we have demonstrated that islet amyloid
deposition in human pancreatic islets is associated with
decreased -cell area and increased -cell apoptosis. In
addition, -cell apoptosis was associated with de-
creased -cell area. Our data therefore support a role
for the accumulation of amyloid in the loss of  cells in
type 2 diabetes and suggest that interventions aimed
at limiting or preventing islet amyloid deposition may
have beneficial effects in preserving -cell mass in
type 2 diabetes.
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